| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1035364722 |
| P356 | DOI | 10.1007/BF03256329 |
| P8608 | Fatcat ID | release_4ln5d2pzljccbnszn2dn5vf2ly |
| P3181 | OpenCitations bibliographic resource ID | 3566601 |
| P698 | PubMed publication ID | 19712003 |
| P2093 | author name string | Saud A. Sadiq | |
| Violaine K. Harris | |||
| P2860 | cites work | A stop-codon mutation in the BRI gene associated with familial British dementia | Q22010197 |
| Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: Beta-amyloid(1-42), tau, phospho-tau-181 and total protein | Q22241541 | ||
| Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease | Q22248076 | ||
| Environmental risk factors for multiple sclerosis. Part I: The role of infection | Q22252937 | ||
| Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein | Q22253157 | ||
| Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders | Q24300724 | ||
| The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production | Q24306233 | ||
| BRI2 interacts with amyloid precursor protein (APP) and regulates amyloid beta (Abeta) production | Q24308675 | ||
| BRI2 (ITM2b) inhibits Abeta deposition in vivo | Q24319041 | ||
| Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis | Q24650147 | ||
| Inhibitor of neurite outgrowth in humans | Q28144415 | ||
| Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1 | Q28144424 | ||
| Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event | Q28186287 | ||
| The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease | Q28207482 | ||
| Cleavage of cystatin C is not associated with multiple sclerosis | Q28265824 | ||
| Proteomic analysis of multiple sclerosis cerebrospinal fluid | Q28269026 | ||
| Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist | Q28281644 | ||
| The neuropsychiatry of multiple sclerosis: a review of recent developments | Q28296987 | ||
| Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions | Q28366501 | ||
| Risk alleles for multiple sclerosis identified by a genomewide study | Q29614890 | ||
| The clinico-radiological paradox in multiple sclerosis revisited | Q30696042 | ||
| Imaging neuronal and axonal degeneration in multiple sclerosis | Q30885236 | ||
| The impact of our genes: consequences of the apolipoprotein E polymorphism in Alzheimer disease and multiple sclerosis | Q31037583 | ||
| Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. | Q31132463 | ||
| Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis | Q33232505 | ||
| Cystatin C in cerebrospinal fluid and multiple sclerosis | Q33253507 | ||
| Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis | Q33256695 | ||
| Cerebrospinal fluid proteome profile in multiple sclerosis | Q33299647 | ||
| Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis | Q33313473 | ||
| Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. | Q33319975 | ||
| N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry | Q33556095 | ||
| Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis | Q33642743 | ||
| Inducible nitric oxide synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute, but not in chronic, multiple sclerosis. | Q33997314 | ||
| Nitric oxide and blood-brain barrier integrity | Q34276274 | ||
| Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. | Q34479121 | ||
| Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis | Q81347142 | ||
| Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study | Q81515064 | ||
| Protection of research subjects | Q95816670 | ||
| Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele | Q44281641 | ||
| Detection of the 14-3-3 protein in the cerebrospinal fluid of Japanese multiple sclerosis patients presenting with severe myelitis | Q44480140 | ||
| Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology | Q44555753 | ||
| Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis | Q44560635 | ||
| Increased 14-3-3 immunoreactivity in glial elements in patients with multiple sclerosis | Q44647503 | ||
| Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy | Q44685789 | ||
| Antibodies against Epstein-Barr virus and herpesvirus type 6 are associated with the early phases of multiple sclerosis | Q44866997 | ||
| Plasma osteopontin levels in multiple sclerosis. | Q45180843 | ||
| Cerebrospinal fluid myelin basic protein immunoreactivity as an indicator of brain damage in children | Q45261040 | ||
| Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis | Q46157365 | ||
| Interferon beta 1-b in verbal memory functioning of patients with relapsing-remitting multiple sclerosis | Q46200872 | ||
| Identification of autoantibodies associated with myelin damage in multiple sclerosis | Q46424597 | ||
| A randomized clinical trial of valacyclovir in multiple sclerosis | Q46548027 | ||
| Soluble Nogo-A in CSF is not a useful biomarker for multiple sclerosis | Q46582323 | ||
| Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease | Q46707483 | ||
| Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution | Q46814966 | ||
| Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination | Q46968199 | ||
| No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis | Q47276347 | ||
| Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis | Q47276359 | ||
| Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients | Q47279465 | ||
| Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. | Q47357498 | ||
| Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis. | Q47442661 | ||
| MxA Gene Expression Analysis as an Interferon-β Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity | Q47583383 | ||
| Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis | Q47735680 | ||
| Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. | Q47767870 | ||
| Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-epsilon 4. | Q47866571 | ||
| Nitric oxide as an activity marker in multiple sclerosis | Q47926902 | ||
| Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. | Q48149612 | ||
| Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions | Q48182289 | ||
| APOE epsilon 4 allele is associated with cognitive impairment in patients with multiple sclerosis | Q48187897 | ||
| Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. | Q48200750 | ||
| Subpial demyelination in the cerebral cortex of multiple sclerosis patients | Q48233815 | ||
| Antimyelin antibodies with no progression to multiple sclerosis. | Q48298505 | ||
| Lack of association between antimyelin antibodies and progression to multiple sclerosis | Q48298518 | ||
| The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study | Q48335809 | ||
| Tetranectin in cerebrospinal fluid of patients with multiple sclerosis. | Q48371726 | ||
| Increased release of interleukin-12p40 in MS: association with intracerebral inflammation | Q48390502 | ||
| Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy | Q48400490 | ||
| Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study | Q48408024 | ||
| Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry | Q48477701 | ||
| Cerebrospinal fluid and serum nitric oxide metabolites in patients with multiple sclerosis | Q48494263 | ||
| A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination | Q48530177 | ||
| Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit | Q48605590 | ||
| Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment | Q48701331 | ||
| Cortical demyelination and diffuse white matter injury in multiple sclerosis. | Q48726181 | ||
| Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions | Q48822577 | ||
| The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis | Q48823169 | ||
| Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. | Q48853343 | ||
| Up-regulation of osteopontin and alphaBeta-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays | Q48892536 | ||
| Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. | Q48894792 | ||
| Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein | Q48931070 | ||
| IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles | Q48934460 | ||
| Cerebrospinal fluid myelin basic protein as a prognostic marker in patients with head injury | Q49305384 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Transplantation of human neural stem cells for spinal cord injury in primates. | Q51527726 | ||
| Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. | Q51763866 | ||
| Proteomic analysis of human cerebral endothelial cells activated by multiple sclerosis serum and IFNbeta-1b. | Q52582180 | ||
| Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. | Q53471810 | ||
| The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. | Q53851476 | ||
| Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. | Q53877418 | ||
| CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis. | Q54077161 | ||
| Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. | Q54509774 | ||
| Interferon receptor expression in multiple sclerosis patients. | Q54565439 | ||
| Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. | Q54601819 | ||
| Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. | Q54788025 | ||
| Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. | Q55039401 | ||
| CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS | Q57602005 | ||
| High CSF neurofilament heavy chain levels in neuromyelitis optica | Q57725968 | ||
| Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis | Q57912405 | ||
| Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations | Q59273833 | ||
| Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. | Q34491595 | ||
| Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy | Q34578618 | ||
| Extensive cortical remyelination in patients with chronic multiple sclerosis. | Q34612670 | ||
| Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. | Q34653997 | ||
| Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. | Q34657019 | ||
| The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. | Q34673142 | ||
| Multiple sclerosis: an immune or neurodegenerative disorder? | Q34786872 | ||
| The 14-3-3 protein epsilon isoform expressed in reactive astrocytes in demyelinating lesions of multiple sclerosis binds to vimentin and glial fibrillary acidic protein in cultured human astrocytes | Q35103017 | ||
| The role of nitric oxide in multiple sclerosis | Q35172450 | ||
| Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. | Q35466511 | ||
| Anti-IFN BAb and NAb antibodies: a minireview | Q35580806 | ||
| Identification of molecular biomarkers for multiple sclerosis | Q35789583 | ||
| Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein | Q35818687 | ||
| Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event | Q36142086 | ||
| Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. | Q36381085 | ||
| The value of animal models for drug development in multiple sclerosis. | Q36458937 | ||
| Epidemiology and natural history of multiple sclerosis: new insights | Q36479921 | ||
| The role of TRAIL/TRAIL receptors in central nervous system pathology | Q36813631 | ||
| Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event | Q36824348 | ||
| Cerebrospinal fluid markers in Creutzfeldt-Jakob disease | Q36865663 | ||
| A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis | Q36891696 | ||
| Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature | Q37242816 | ||
| Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses | Q37712459 | ||
| Cerebrospinal fluid levels of brain specific proteins in optic neuritis | Q38339554 | ||
| Neuropsychologic status in multiple sclerosis after treatment with glatiramer | Q38450118 | ||
| Cerebrospinal Fluid Myelin Basic Protein and Multiple Sclerosis | Q39509340 | ||
| TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. | Q40172029 | ||
| TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis | Q40580264 | ||
| Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells | Q40733996 | ||
| Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. | Q40864697 | ||
| Apolipoprotein E alleles as risk factors in Alzheimer's disease | Q41036434 | ||
| Interleukin-6 is elevated in plasma in multiple sclerosis | Q41177826 | ||
| High prevalence of anti-alpha-crystallin antibodies in multiple sclerosis: correlation with severity and activity of disease | Q41689185 | ||
| Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone | Q43562148 | ||
| 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis | Q43721324 | ||
| N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve | Q43849057 | ||
| Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. | Q43874500 | ||
| MR correlates of cerebral atrophy in patients with multiple sclerosis. | Q44114075 | ||
| Elevated osteopontin levels in active relapsing-remitting multiple sclerosis | Q44140769 | ||
| Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts initial observations | Q44159266 | ||
| Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels | Q44197130 | ||
| Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis | Q59273850 | ||
| Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies | Q59273881 | ||
| Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis | Q60169773 | ||
| A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease | Q68834759 | ||
| Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis | Q68974225 | ||
| Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis | Q70114371 | ||
| Simultaneous measurement of 2':3' cyclic-nucleotide 3' phosphodiesterase and RNase activities in sera and spinal fluids of multiple sclerosis patients | Q70176298 | ||
| Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains | Q71659583 | ||
| The adhesion molecule and cytokine profile of multiple sclerosis lesions | Q71688111 | ||
| Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization | Q72427037 | ||
| Nitric oxide metabolites in CSF of patients with MS are related to clinical disease course | Q73187442 | ||
| Interleukin-12 and tumor necrosis factor-alpha levels in cerebrospinal fluid of multiple sclerosis patients | Q73230710 | ||
| Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients | Q73298573 | ||
| In vitro expression of N-acetyl aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo | Q73315910 | ||
| Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury | Q73385164 | ||
| Anti-alpha B-crystallin immunoreactivity in inflammatory nervous system diseases | Q73493900 | ||
| Increased cerebrospinal fluid tau protein in multiple sclerosis | Q73828468 | ||
| Antibodies to myelin basic protein, myelin oligodendrocytes peptides, alpha-beta-crystallin, lymphocyte activation and cytokine production in patients with multiple sclerosis | Q73943317 | ||
| Changes in nitrite and nitrate (NO2-/NO3-) levels in cerebrospinal fluid of patients with multiple sclerosis | Q74142796 | ||
| IL-6 and sIL-6R concentration in the cerebrospinal fluid and serum of MS patients | Q74460100 | ||
| Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS | Q75205821 | ||
| Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability | Q77451316 | ||
| Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group | Q77573170 | ||
| Increased intrathecal nitric oxide formation in multiple sclerosis; cerebrospinal fluid nitrite as activity marker | Q78158199 | ||
| Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients | Q78555305 | ||
| Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis | Q78596324 | ||
| The measurement of antibodies binding to IFNβ in MS patients treated with IFNβ | Q79279426 | ||
| Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis | Q79622636 | ||
| Detection of anti-Nogo receptor autoantibody in the serum of multiple sclerosis and controls | Q79763166 | ||
| APOE genotypes in Greek multiple sclerosis patients: no effect on the MS Severity Score | Q79898157 | ||
| Nogo-A is a reliable oligodendroglial marker in adult human and mouse CNS and in demyelinated lesions | Q79932421 | ||
| Acute transverse myelitis with normal brain MRI : long-term risk of MS | Q80201378 | ||
| Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis | Q80298286 | ||
| Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis | Q80347950 | ||
| Soluble interleukin-6 receptor (sIL-6R) in cerebrospinal fluid of patients with inflammatory and non inflammatory neurological diseases | Q80382472 | ||
| Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients | Q80516387 | ||
| Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis | Q80682046 | ||
| Old suspects found guilty--the first genome profile of multiple sclerosis | Q80693902 | ||
| Predictive markers for response to interferon therapy in patients with multiple sclerosis | Q80695185 | ||
| Antibodies against light neurofilaments in multiple sclerosis patients | Q80697259 | ||
| The 14-3-3 protein in multiple sclerosis: a marker of disease severity | Q80835968 | ||
| Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients | Q80853050 | ||
| CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis | Q80908158 | ||
| Neurofilament and glial fibrillary acidic protein in multiple sclerosis | Q80980689 | ||
| Expression pattern of NOGO-A protein in the human nervous system | Q81192764 | ||
| Evidence for human herpesvirus 6 variant A antibodies in multiple sclerosis: diagnostic and therapeutic implications | Q81236151 | ||
| Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera | Q81339980 | ||
| P433 | issue | 4 | |
| P921 | main subject | biomarker | Q864574 |
| multiple sclerosis | Q8277 | ||
| P304 | page(s) | 225-244 | |
| P577 | publication date | 2009-08-01 | |
| P1433 | published in | Molecular Diagnosis and Therapy | Q15758832 |
| P1476 | title | Disease Biomarkers in Multiple Sclerosis | |
| P478 | volume | 13 |
| Q42572288 | 14-3-3ζ: A numbers game in adipocyte function? |
| Q38056688 | Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis |
| Q35364112 | Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel |
| Q90531420 | Biomarkers of multiple sclerosis: current findings |
| Q27012726 | Biomarkers of therapeutic response in multiple sclerosis: current status |
| Q38984981 | Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases |
| Q48190297 | Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: implication in peripheral inflammation. |
| Q34370127 | CSF isoprostane levels are a biomarker of oxidative stress in multiple sclerosis |
| Q48149436 | Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis |
| Q34981487 | Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases |
| Q38088728 | Clinical biomarkers in multiple sclerosis |
| Q36303187 | Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS) |
| Q49074970 | Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development |
| Q28535303 | Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis |
| Q35795093 | Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis |
| Q34718044 | Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. |
| Q84622973 | Leuprolide acetate, a GnRH agonist, improves experimental autoimmune encephalomyelitis: a possible therapy for multiple sclerosis |
| Q34197306 | MS14, a Marine Herbal Medicine, an Immunosuppressive Drug in Experimental Autoimmune Encephalomyelitis. |
| Q37943855 | Microfluidic strategies applied to biomarker discovery and validation for multivariate diagnostics |
| Q38079620 | Multiple sclerosis: individualized disease susceptibility and therapy response. |
| Q50766038 | Nanoneurobiophysics: new challenges for diagnosis and therapy of neurologic disorders. |
| Q42201440 | Optimizing multiple sclerosis diagnosis: gene expression and genomic association. |
| Q36377677 | Osteopontin in Immune-mediated Diseases |
| Q52719321 | Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients. |
| Q37812799 | Proteomics of human cerebrospinal fluid: Discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics |
| Q27006644 | Role of osteopontin in systemic lupus erythematosus |
| Q38853978 | Serum complement factor H and Tyr402 His gene polymorphism among Egyptians with multiple sclerosis |
| Q41020428 | Sildenafil, a Phosphodiesterase Type 5 Inhibitor, Downregulates Osteopontin in Human Peripheral Blood Mononuclear Cells |
| Q49834181 | Subsets of activated monocytes and markers of inflammation in incipient and progressed multiple sclerosis |
| Q36015388 | Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of multiple sclerosis |
| Q37333860 | The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis |
| Q38819421 | The cerebrospinal fluid in multiple sclerosis: far beyond the bands |
| Q40911558 | The clinical significance of the neutrophil-to-lymphocyte ratio in multiple sclerosis |
| Q96134698 | The preliminary association study of osteopontin 707 C/T polymorphism with systemic lupus erythematosus in a Polish population |
| Q37216886 | The role of chromogranin B in an animal model of multiple sclerosis |
| Q97563232 | Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations |
| Q30578168 | Using gene expression data to identify certain gastro-intestinal diseases |
Search more.